Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms

Non-Hodgkin lymphoma (NHL) is the most commonly diagnosed hematologic cancer of adults in the United States, with the vast majority of NHLs deriving from malignant B lymphocytes that express cell surface CD20. CD20 immunotherapy (rituximab) is widely used to treat NHL, even though the initial effect...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Lykken, Jacquelyn M., Horikawa, Mayuka, Minard-Colin, Veronique, Kamata, Masahiro, Miyagaki, Tomomitsu, Poe, Jonathan C., Tedder, Thomas F.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2016
Teme:
Immunobiology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4832507/
https://ncbi.nlm.nih.gov/pubmed/26888257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-681130
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki